GE Healthcare and pharmaceutical giant Roche announced a partnership to collectively develop and co-market digital clinical decision support solutions.
Oncology care and treatments are emerging as among the most popular applications of precision medicine thus far. Late last year, for instance, the U.S. Food and Drug Administration approved and the Centers for Medicare and Medicaid Services said it would reimburse doctors for using a breakthrough test to pinpoint cancer biomarkers. And as a number of enterprise, IT companies move into healthcare eyeing precision medicine, the University of California San Diego Center for Personalized Cancer Therapy ran a test with startup CureMatch using a supercomputer that determined successful cancer treatments where doctors had previously failed.
GE Healthcare and Roche said they will focus on precision medicine products to accelerate and improve individualized treatments for cancer and critical care patients.
The mission is to develop a digital platform using advanced analytics to provide workflow solutions and apps to support clinical decisions. This, they say, will allow the seamless integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real-time monitoring and the latest research outcomes.
The companies said that the platform will include a data dashboard that care teams can use to review, collaborate and align with treatment decisions for cancer patients at each stage of their disease.
In the critical care setting, data from a patient’s hospital monitoring equipment will be integrated with their biomarker, tissue pathology, genomic and sequencing data, which will help physicians to identify, or predict severe complications before they occur.